Efficacy and Safety of the Oral Gonadotropin‐Releasing Hormone Antagonist DW4902 for Heavy Menstrual Bleeding in Uterine Fibroids: A Randomized, Double‐Blind, Placebo‐Controlled Phase II Trial
BJOG: An International Journal of Obstetrics & Gynaecology · 18.11.2026
DOI: 10.1111/1471-0528.70385 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJOG: An International Journal of Obstetrics & Gynaecology, online erschienen am 18.11.2026. Verfasst von Jae‐yeon Song und 12 weiteren Autor:innen. Die Arbeit nennt 52 Literaturangaben.
Abstract (Originalsprache)
Objective
To evaluate the efficacy and safety of DW4902, a novel oral gonadotropin‐releasing hormone (GnRH) antagonist, in premenopausal women with uterine fibroids and heavy menstrual bleeding (HMB).
Design
Multicenter, randomized, double‐blind, placebo‐controlled Phase II trial.
Setting
Twelve tertiary hospitals in Korea. Population Premenopausal women with uterine fibroids and heavy menstrual bleeding, defined as a screening pictorial blood assessment chart score (PBAC) ≥ 120.
Methods
Seventy‐one women with uterine fibroids, HMB (screening PBAC ≥ 120) and other predefined criteria were randomized to placebo or DW4902 160, 240 or 320 mg once daily. Main Outcome Measures The primary endpoint was the proportion achieving PBAC < 10 during Weeks 6–12. Secondary endpoints included amenorrhea, haemoglobin change, fibroid and uterine volumes, pain scores, bone mineral density and safety.
Results
During Weeks 6–12, PBAC < 10 was achieved by 73.33%–100.00% of participants receiving DW4902 160, 240 and 320 mg ( p < 0.0001). Amenorrhea rates were likewise significantly higher in the DW4902 groups (≥ 73.33%), with bleeding suppression evident from Weeks 2 to 6. Haemoglobin levels increased significantly in the 160 and 240 mg groups. Fibroid and uterine volumes and fibroid‐related pain were significantly reduced across all DW4902 dose groups. Hormone levels recovered after treatment discontinuation, and lumbar spine bone mineral density showed modest, reversible changes. Adverse events were mostly mild and comparable between groups, with no serious drug‐related events.
Conclusions
DW4902 demonstrated a robust efficacy in reducing menstrual bleeding and improving fibroid‐related outcomes with an acceptable short‐term safety and bone density profile.
Zitieren
APA
Song, J., Park, J. Y., Choi, Y. S., Lee, D., Kim, S. E., Lee, J. R., Yi, K. W., Cho, S., Chi‐Heum, C., Kim, M., Joo, J. K., Shin, J., & Kim, S. H. (2026). Efficacy and Safety of the Oral Gonadotropin‐Releasing Hormone Antagonist DW4902 for Heavy Menstrual Bleeding in Uterine Fibroids: A Randomized, Double‐Blind, Placebo‐Controlled Phase II Trial. BJOG: An International Journal of Obstetrics & Gynaecology. https://doi.org/10.1111/1471-0528.70385
Vancouver
Song J, Park JY, Choi YS, Lee D, Kim SE, Lee JR, et al. Efficacy and Safety of the Oral Gonadotropin‐Releasing Hormone Antagonist DW4902 for Heavy Menstrual Bleeding in Uterine Fibroids: A Randomized, Double‐Blind, Placebo‐Controlled Phase II Trial. BJOG: An International Journal of Obstetrics & Gynaecology. 2026. doi:10.1111/1471-0528.70385
BibTeX
@article{Song2026,
author = {Song, Jae‐yeon and Park, Jung Yoon and Choi, Young Sik and Lee, Dong‐Yun and Kim, Sung Eun and Lee, Jung Ryeol and Yi, Kyong Wook and Cho, SiHyun and Chi‐Heum, Cho and Kim, Miran and Joo, Jong Kil and Shin, Jung‐Ho and Kim, Sung Hoon},
title = {Efficacy and Safety of the Oral Gonadotropin‐Releasing Hormone Antagonist DW4902 for Heavy Menstrual Bleeding in Uterine Fibroids: A Randomized, Double‐Blind, Placebo‐Controlled Phase II Trial},
journal = {BJOG: An International Journal of Obstetrics & Gynaecology},
year = {2026},
doi = {10.1111/1471-0528.70385}
}
EUVIMED